Fennec Pharmaceuticals

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fennec Pharmaceuticals reports Q1 loss, sees growth in new therapies

Fennec Pharmaceuticals' Q1 2023 earnings call highlighted a mix of financial results, market strategies, and analyst inquiries. Despite challenges in achieving profitability, the company showcased strengths in product launches and market acceptance. Opportunities for growth through expanded adoption, market strategies, and R&D investments were discussed.

Fennec Pharmaceuticals reports robust revenue growth and strategic milestones in Q2 2023

Fennec Pharmaceuticals demonstrated strong revenue growth and key regulatory milestones in Q2 2023, positioning the company for future success.
While facing financial challenges and operational inquiries, Fennec's strategic focus on commercial expansion and patient support programs remains a key strength.
With a solid cash position and experienced leadership, Fennec is well-positioned to capitalize on market opportunities and drive further growth in the oncology sector.

Fennec Pharmaceuticals excels in Q3 with PEDMARK growth strategies

Fennec Pharmaceuticals demonstrated robust financial performance and strategic market positioning in Q3 2023, leveraging the successful launch of PEDMARK in the U.S. and plans for European expansion.
While facing challenges in metrics tracking, manufacturing transitions, and pipeline prioritization, the company remains focused on maximizing PEDMARK's market potential and competitive edge.
Opportunities lie in expanding market presence in Europe, negotiating favorable pricing strategies, and solidifying PEDMARK's position as a key therapy alongside cisplatin.

Fennec Pharmaceuticals excels in Q4 2023, secures strategic partnerships

Fennec Pharmaceuticals delivered strong financial results and strategic advancements in Q4 2023, positioning the company for growth.
While facing challenges in increased expenses and access barriers, Fennec's focus on pediatric oncology and strategic partnerships offer promising opportunities.
With a solid financial foundation and market endorsements, Fennec is well-positioned to capitalize on its growth potential and expand its market presence.

Fennec Pharmaceuticals reports solid Q1 performance amidst market challenges

Fennec Pharmaceuticals navigated challenges in Q1 2024 while maintaining strong financial performance and strategic advancements. The company's focus on resolving issues, expanding market reach, and optimizing sales strategies positions it for future success.

Fennec Pharmaceuticals reports solid Q2 performance, eyes market expansion

Fennec Pharmaceuticals' Q2 2024 performance reflects progress in PEDMARK's commercialization and market access.
While facing challenges in specific business segments, the company's strong financial position and strategic partnerships are notable strengths.
Opportunities lie in targeted market expansion and clear communication of growth strategies to investors.

Fennec Pharmaceuticals reports robust Q3 performance and eyes international expansion

Fennec Pharmaceuticals showcased solid financial performance in Q3 2024, with a strong focus on the AYA market.
The company's strategic imperatives for PEDMARK and leadership enhancements position it for future growth.
While challenges exist in increasing awareness and managing expenses, opportunities in revenue growth and market expansion are promising.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)---- $FENC #FENC--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fennec Pharmaceuticals Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $FENC #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Fennec Pharmaceuticals Inc.

The Law Offices of Frank R. Cruz Announces Investigation of Fennec Pharmaceuticals Inc.

BENSALEM, Pa.--(BUSINESS WIRE)---- $FENC #fraud--INVESTOR ALERT: Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fennec Pharmaceuticals Inc.

LOS ANGELES--(BUSINESS WIRE)---- $FENC #FENC--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fennec Pharmaceuticals Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) resulting from allegations that Fennec may have issued materially misleading business information to the investing public.

EQUITY ALERT: ROSEN, A LEADING AND RANKED FIRM, Announces Investigation of Securities Claims Against Fennec Pharmaceuticals Inc. – FENC

At $8.50/share FENC's market cap is $240MM, and its enterprise valuation is $200MM. FENC has only one program or asset in development called Pedmark.

Ultimate Valuation Inflection Point Rapidly Approaching For Fennec Pharmaceuticals (Pedmark PDUFA Date August 10, 2020)

~ FDA Set a PDUFA Target Action Date for  PEDMARKTM   of August 10, 2020 ~  ~  Strong Financial Position with $38.7 million in cash and no debt  ~

Fennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

~ FDA Set a PDUFA Target Action Date for  PEDMARKTM   of August 10, 2020 ~  ~  Marketing Authorization Application (MAA) Validated by the EMA in February 2020  ~  ~  Strengthened its Financial Position Through a Raise of Approximately $32 Million in Net Proceeds ~  ~  Commercial Readiness Activities are Underway in the U.S.  ~

Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update

RESEARCH TRIANGLE PARK, N.C., May  08, 2020  (GLOBE NEWSWIRE) --  Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that in connection with its previously completed underwritten offering on May 4, 2020 of $30,000,000 at a price of $6.25 per share, the option granted to the underwriters was exercised for 660,204 shares at a price of $6.25 per share for additional gross proceeds of $4,126,275. The sale of the additional shares under the exercise of the underwriters’ option brings the total aggregate proceeds from the offering (before deducting the underwriting discounts and offering expenses) to $34,126,275.

Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

RESEARCH TRIANGLE PARK, N.C., May  05, 2020  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the closing of its previously announced underwritten public offering of 4,800,000 common shares at a public offering price of $6.25 per share. In addition, Fennec has granted the underwriters a 30-day option to purchase up to an additional 720,000 common shares. The total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) is $30,000,000, excluding any exercise of the underwriters’ option to purchase additional shares.

Fennec Announces Closing of Public Offering

RESEARCH TRIANGLE PARK, N.C., April  30, 2020  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the pricing of its underwritten public offering of 4,800,000 common shares at a public offering price of $6.25 per share. In addition, Fennec has granted the underwriters a 30-day option to purchase up to an additional 720,000 common shares. Fennec anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) will be $30 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on May 4, 2020, subject to customary closing conditions.

Fennec Announces Pricing of Public Offering

RESEARCH TRIANGLE PARK, N.C., April  29, 2020  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that it intends to offer its common shares in an underwritten public offering. In addition, Fennec intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its common shares offered in the public offering.

Fennec Announces Proposed Public Offering of Common Shares

~ Potential for PEDMARK to be the First Product for the Prevention of Cisplatin-Induced Hearing Loss in Children ~

Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK™

RESEARCH TRIANGLE PARK, N.C., March  05, 2020  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,596,190 entitled “Method for Reducing Ototoxicity in Pediatric Patients Receiving Platinum-Based Chemotherapy.”  As suggested by the title, the patent captures the use of Fennec’s PEDMARK product to reduce the ototoxic effects of cisplatin in pediatric patients, particularly in the age group of five years or younger.  This is U.S Food and Drug Administration (FDA) Orange Book eligible U.S. patent, and reflects Fennec’s strategy to expand and diversify its intellectual property portfolio to obtain protection for the PEDMARK product.

Fennec Announces Issuance of U.S. Patent for Use of PEDMARK™

Potential First Product in Europe for the Prevention of Cisplatin-Induced Hearing Loss in Children Potential First Product in Europe for the Prevention of Cisplatin-Induced Hearing Loss in Children

Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate

Fennec Pharmaceuticals: Market Fatigue Due To A Lack Of Catalysts Has Created A Mispricing - Behind The Idea

PEDMARK™ is Being Developed for Prevention of Cisplatin-Induced Hearing Loss in Children PEDMARK™ is Being Developed for Prevention of Cisplatin-Induced Hearing Loss in Children

Fennec Pharmaceuticals Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for PEDMARK™ and Also Submits Marketing Authorization Application (MAA) to European Medicines Agency

As of late, it has definitely been a great time to be an investor in Fennec Pharmaceuticals Inc. (FENC).

Fennec Pharmaceuticals Inc. (FENC) Shares March Higher, Can It Continue?

RESEARCH TRIANGLE PARK, N.C., Oct.  02, 2019  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that Rosty Raykov, Chief Executive Officer of Fennec, will present at the Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4th, at 1:45 pm ET.

Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019

RESEARCH TRIANGLE PARK, N.C., Sept.  24, 2019  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has appointed Jodi A. Cook, PhD to its board of directors. Dr. Cook currently serves as Head of Gene Therapy Strategy at PTC Therapeutics, Inc., a global biopharmaceutical company focused on the development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Prior to joining PTC Therapeutics, she was one of the founding members and Chief Operating Officer of Agilis Biotherapeutics, a clinical-stage company focused on gene therapies for patients with rare diseases. Importantly, her career spans a wide range of experience relevant to Fennec’s business interests including Assistant Professor of Audiology and Director of the Hearing Aid Program at Mayo Clinic, and executive positions in a number of successful biotech start-ups within the hearing industry. While at Agilis, she led the sale of the company to PTC Therapeutics in a deal that has represented significant value to all parties.

Fennec Appoints Jodi A. Cook, PhD to Its Board of Directors

Seasoned commercial leader to lead the anticipated launch of PEDMARK™ Seasoned commercial leader to lead the anticipated launch of PEDMARK™

Fennec Appoints Shubh Goel as Chief Commercial Officer

Shares of Fennec are punished following the company announcing a setback in NDA submission.

Fennec Stumbles On NDA Delay

Within my exclusive marketplace, The Formula, I follow transitioning biotechnology companies, backed by smart money (institutions), that possess one or more assets with therapeutic differentiation & competitive advantages.

News for Fennec Pharmaceuticals Stock (FENC)